A detailed history of Simplex Trading, LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Simplex Trading, LLC holds 2,413 shares of ADCT stock, worth $4,826. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,413
Previous 1,938 24.51%
Holding current value
$4,826
Previous $6,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$2.59 - $4.01 $1,230 - $1,904
475 Added 24.51%
2,413 $7,000
Q2 2024

Jul 25, 2024

SELL
$2.55 - $5.09 $32,683 - $65,238
-12,817 Reduced 86.87%
1,938 $6,000
Q1 2024

Apr 25, 2024

BUY
$1.66 - $5.29 $22,536 - $71,817
13,576 Added 1151.48%
14,755 $66,000
Q4 2023

Feb 02, 2024

SELL
$0.47 - $1.79 $24 - $94
-53 Reduced 4.3%
1,179 $1,000
Q3 2023

Nov 01, 2023

BUY
$0.72 - $2.37 $280 - $924
390 Added 46.32%
1,232 $1,000
Q2 2023

Aug 04, 2023

BUY
$1.9 - $2.66 $1,286 - $1,800
677 Added 410.3%
842 $1,000
Q1 2023

Apr 27, 2023

SELL
$1.92 - $5.45 $4,638 - $13,167
-2,416 Reduced 93.61%
165 $0
Q4 2022

Feb 02, 2023

SELL
$2.87 - $5.24 $18,256 - $33,331
-6,361 Reduced 71.14%
2,581 $9,000
Q3 2022

Nov 04, 2022

BUY
$4.66 - $10.31 $41,669 - $92,192
8,942 New
8,942 $43,000
Q1 2022

May 02, 2022

SELL
$13.28 - $20.03 $1,181 - $1,782
-89 Closed
0 $0
Q4 2021

Feb 23, 2022

BUY
$19.29 - $31.51 $1,716 - $2,804
89 New
89 $1,000
Q2 2021

Aug 12, 2021

SELL
$20.38 - $27.04 $19,075 - $25,309
-936 Closed
0 $0
Q1 2021

Apr 26, 2021

BUY
$22.75 - $34.05 $14,355 - $21,485
631 Added 206.89%
936 $22,000
Q4 2020

Feb 02, 2021

SELL
$25.26 - $38.02 $3,359 - $5,056
-133 Reduced 30.37%
305 $9,000
Q3 2020

Oct 14, 2020

BUY
$32.87 - $51.05 $14,397 - $22,359
438 New
438 $14,000

Others Institutions Holding ADCT

About ADC Therapeutics SA


  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $155M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.